ヒーリーALSマイマッチ共通スクリーニングプロトコル (MCSP)
ALS MyMatch早期段階臨床試験の予備適格性を判断するためのHealey ALS MyMatch共通スクリーニングプロトコル(MCSP)
The Healey ALS MyMatch Common Screening Protocol (MCSP) is an observational study. The main goal of the study is to help connect adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
People who complete an MCSP Screening Visit will undergo:
- clinical assessments
- laboratory testing
- biomarker analyses
The above will be used to determine preliminary eligibility for enrolling ALS MyMatch trials. In addition to helping connect people to a Healey ALS MyMatch interventional clinical trial, the information will also be used to characterize clinical, genetic, and biofluid biomarker profiles. These profiles will help to match the right people to the right trials and evaluate the frequency of ALS-associated gene variants. Blood samples and DNA will also be stored for future ALS and biomarker research.
調査の概要
状態
詳細な説明
The MyMatch Common Screening Protocol (MCSP) is an observational study that is part of the Healey ALS MyMatch program. Healey ALS MyMatch is an early phase (Phase 1b or 2a), Amyotrophic Lateral Sclerosis (ALS) clinical trial program. ALS MyMatch is designed to help match adults living with ALS to Healey ALS MyMatch interventional clinical trials that may be a good fit for them.
The first step in participating in Healey ALS MyMatch is to complete a screening visit for the MCSP. MCSP screening visit activities can be completed over a period of 45-days and some screening visit activities can be completed remotely. MCSP screening visit activities include:
- obtaining informed consent
- reviewing medical history
- collecting blood samples
- completing a 12-lead ECG
- completing questionnaires
To be eligible to participate in the MCSP, the following key criteria will need to be met: ALS diagnosis, SVC breathing score of equal to or greater than 65%, and ALS genetic testing.
The information collected at the MCSP screening visit helps researchers determine whether a participant might qualify for one or more treatment studies that are currently enrolling in the ALS MyMatch program. If a participant appears eligible for more than one study, then the participant may choose to consult with their doctor and decide which study would be a better fit for them.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Healey ALS MyMatch Clinical Operations Team
- 電話番号:857-282-9210
- メール:mghalsmymatch@mgb.org
研究場所
-
-
Florida
-
Davie、Florida、アメリカ、33314
- まだ募集していません
- Nova Southeastern University
-
コンタクト:
- Donovan Mott
- 電話番号:954-203-2829
- メール:Donovan.mott@nova.edu
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- まだ募集していません
- Northwestern University
-
コンタクト:
- Candace James
- 電話番号:312-503-0747
- メール:candace.james@northwestern.edu
-
コンタクト:
- ALS Research
- メール:alsresearch@northwestern.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General Hospital
-
コンタクト:
- Hattie Grant
- 電話番号:617-643-7912
- メール:healeysitemymatchmgh@mgb.org
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55414
- まだ募集していません
- University of Minnesota
-
コンタクト:
- Tori Schirrick
- 電話番号:(612) 626-7300
- メール:kaste125@umn.edu
-
コンタクト:
- Julia Munoz
- 電話番号:(612)-624-9987
- メール:munoz156@umn.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The target populations for MCSP and ALS MyMatch trials will initially focus on subgroups of individuals with ALS, including those with early-stage disease. Some ALS MyMatch trials will further target those with specific biomarkers or genetic markers for inclusion in a specific trial.
説明
Inclusion Criteria:
- Ability to provide written informed consent.
- Adults > 18 years of age.
- Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.
- Available or pending clinically obtained CLIA ALS genetic panel report.
- Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.
- Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.
- Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g/dL.
- Ability and willingness to complete all study procedures per SI's assessment.
- Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).
Exclusion Criteria:
-
Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.
-
Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.
-
Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)
-
Prior solid organ transplantation.
-
Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)
-
Screening 12-lead ECG showing QT interval corrected for rate (QTcF) > 470 msec for women and > 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.
-
Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:
- Serum alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal, or serum bilirubin > 1.5 × upper limit of normal
- Estimated GFR (eGFR) of < 30 mL/min/1.73m2
-
Other clinically significant electrolyte and metabolic abnormalities
-
If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.
-
Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.
-
Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
-
Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Preliminary eligibility to be matched to a MyMatch Trial
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
To determine preliminary eligibility of early ALS (< 24 months from weakness onset) participants for actively enrolling ALS MyMatch trial(s) |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Repository for future research
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To build an ALS biofluid, genetic and data repository for future clinical and translational research. |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Prevalence of gene mutations
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To characterize the prevalence of participants with causative or risk modifier gene mutations in the MCSP |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
|
Collect and bank samples
時間枠:From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
To collect and bank blood samples for future biofluid biomarker analyses |
From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. Samples will be banked indefinitely for future research on ALS and related diseases.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2025P002080
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。